QCA First Fund--FFIII Portfolio

QCA First Fund III Portfolio Companies

Collaborent Group creates and markets group purchasing programs for local governments and other public sector entities. The Company’s programs save taxpayer dollars and enable public sector entities to control costs while improving operational efficiencies.

QCA FFIII and individual members of QCA teamed with the North Coast Angel Fund to provide the capital to allow Collaborent to offer more programs to more customers.

Neuros Medical, a Cleveland, Ohio based neurostimulation company, is focused on developing proprietary neurostimulation therapies for unmet needs to patients worldwide. The company’s patented platform technology, Nerve Block, will provide patients with elimination of chronic pain in a variety of applications including neuroma/residual limb pain, chronic post surgical pain, and chronic migraine.

Neuros has been funded through the cooperation of three Third Frontier funds--QCA First Fund III, Ohio TechAngels Fund, and the North Coast Angel Fund, as well as a number of individual investors.

Formerly called Bioformix, Sirrus advances manufacturing technology through chemistry relating to the synthesis, stabilization, activation and formulation of a unique and reactive class of monomers commonly known as methylene malonates. These monomers, their derivatives and resulting polymer platforms provide the foundation for enabling new assembly techniques and energy savings.

The Fund has coordinated with CincyTech and the Queen City Angels to complete the initial funding of the company. A substantial follow-on round was provided by Braemar Energy Ventures and Arsenal Venture Partners.

Blue Ash Therapeutics was formed to bring to market the cardiac drug Azimilide, which was developed by P&G Pharmaceuticals. The drug, which is in the final stages of evaluation by the Food and Drug Administration, helps stabilize cardiac rhythms in in patients who have implantable cardioverter/defibrillators.

QCA FF III participated in the initial funding round which was led by CincyTech and included QCA investors and others. The company was sold to Forest Labs in 2011 for a nice return.

Ischemia Care is commercializing a blood test for the accurate diagnosis of stroke and TIA (Transient Ischemic Attacks). The test, to be used primarily in emergency rooms, will give doctors important additional information to aid in appropriate treatment and to improve outcomes. The technology has been licensed from UC Davis, where it has been under development for many years.

Investment from the Fund was supplemented by individuals in QCA.

EndoSphere is developing a platform of endoscopically implantable devices for the treatment of metabolic diseases, including obesity and type 2 diabetes. EndoSphere's technology causes gradual weight-loss without the cost and complications of surgery.

Investors include QCA First Fund III, QCA members, as well as Ohio TechAngels, North Coast Angel Fund, and others.

CoupSmart has devised a simple, direct way to launch, manage, and measure marketing campaigns for brick and mortar businesses. From retail to consumer goods manufacturers to restaurants or service providers, they help businesses run powerful marketing campaigns via social media, mobile, email, and even in-store.

The Fund combined with a number of individual investors to support the company's growth.